Inhibition of hormone secretion in GH-secreting pituitary adenomas by receptor-subtype specific somatostatin analogues in vitro

General Physiology and Biophysics

Volumn 22, Issue 2, 2003, Pages 201-212

  Cap, Jan ^a   Marekova, M ^a   Cerman, J ^a   Malirova, E ^b   Suba, P ^a   Netuka, D ^a   Hana, V ^a   Marek, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Acromegaly; Pituitary adenoma; Somatostatin analogues; Somatostatin receptor subtypes; Tissue cultures

Indexed keywords

BIM 23197; BIM 23268; GROWTH HORMONE; PROLACTIN; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IN VITRO STUDY; MALE; RANK SUM TEST; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0142155620     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ballare E., Persani L., Lania, A. G., Filopanti M., Giammona E., Corbetta, S., Mantovani S., Arosio M., Beck-Peccoz P., Faglia G., Spada A. (2001): Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86, 3809-3814
2. Freda P. U. (2002): Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87, 3013-3018
3. Greenman Y., Melmed S. (1994a): Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 78, 398-403
4. Greenman Y., Melmed S. (1994b): Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79, 724-729
5. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina, F., Dufour H., Culler M. D., Moreau J. P., Enjalbert A. (1999): Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab. 84, 3268-3276
6. Jaquet P., Saveanu A., Gunz G., Fina F., Zamora A. J., Grino M., Culler M. D., Moreau J. P., Enjalbert A., Ouafik L. H. (2000): Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J. Clin. Endocrinol. Metab. 85, 781-792
7. Lamberts S. W. (1988): The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr. Rev. 9, 417-436
8. Lamberts S. W., Uitterlinden P., Verschoor L., van Dongen K. J., del Pozo E. (1985): Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N. Engl. J. Med. 313, 1576-1580
9. Marek J., Hána, V., Krsek M., Justová V., Catus F., Thomas F. (1994): Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 131, 20-26
10. Melmed S. (1990): Acromegaly. N. Engl. J. Med. 322, 966-977
11. Melmed S., Jackson I., Kleinberg D., Klibanski A. (1998): Current treatment guidelines for acromegaly. J. Clin. Endocrinol. Metab. 83, 2646-2652
12. Miller G. M., Alexander J. M., Bikkal H. A., Katznelson L., Zervas N. T., Klibanski A. (1995): Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 80, 1386-1392
13. Murabe H., Shimatsu A., Ihara, C., Mizuta H., Nakamura Y., Nagata I., Kikuchi H., Nakao K. (1996): Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J. Neuroendocrinol. 8, 605-610
14. Newman C. B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molitch M. E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M. L., Barkan A., Frohman L., Kleinberg D. L. (1998): Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3034-3040
15. Nielsen S., Mellemkjaer S., Rasmussen L. M., Ledet T., Astrup J., Weeke J., Jorgensen J. O. (1998): Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. J. Clin. Endocrinol. Metab. 83, 2997-3000
16. Panetta R., Patel Y. C. (1995): Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 56, 333-342
17. Patel Y. C. (1999): Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157-198
18. Reisine T., Bell G. I. (1995): Molecular biology of somatostatin receptors. Endocr. Rev. 16, 427-442
19. Reubi J. C., Landolt A. M. (1989): The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J. Clin. Endocrinol. Metab. 68, 844-850
20. Ross D. A., Wilson C. B. (1988): Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J. Neurosurg. 68, 854-867
21. Saveanu A., Gunz G., Dufour H., Caron P., Fina F., Ouafik L., Culler M. D., Moreau J. P., Enjalbert A., Jaquet P. (2001): Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab. 86, 140-145
22. Schonbrunn A. (1999): Somatostatin receptors present knowledge and future directions. Ann. Oncol. 10 (Suppl.) 2, S17-21
23. Shimon I., Taylor J. E., Dong J. Z., Bitonte R. A., Kim S., Morgan B., Coy D. H., Culler M. D., Melmed S. (1997a): Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 99, 789-798
24. Shimon I., Yan X., Taylor J. E., Weiss M. H., Culler M. D., Melmed S. (1997b): Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. 100, 2386-2392